Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › United Therapeutics › Director exercised or converted 3,230 UTHR derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Dec 22, 2025
Reporting period Not applicable
Filed with the SEC Dec 24, 2025 Director Indirect holding Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
0001193522-25-000004
Filed / recorded Dec 24, 2025, 2:33 AM UTC
Added to OQRO Oct 6, 2026, 9:34 PM UTC
Data quality Verified: identifiers matched exactly
Issuer UNITED THERAPEUTICS Corp
Reporting person Louis W Sullivan
Table Non-derivative (Table I)
Transaction date Dec 22, 2025
Acquired / disposed Acquired (A)
Ownership form Indirect — by Trust
Footnotes from the filing These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Oct 21, 2025 Insider · 1 person Insiders: 4 sales (~$1.7M) Oct 22, 2025 Insider · 1 person Insiders: 3 sales (~$1.7M) Oct 23, 2025 Insider · 1 person Insiders: 3 sales (~$1.7M) Oct 24, 2025 Insider · 1 person Insiders: 3 sales (~$1.7M) Oct 27, 2025 Insider · 2 people Insiders: 5 sales (~$11.1M) Oct 28, 2025 Insider · 1 person Insiders: 3 sales (~$1.7M) Oct 29, 2025 Company filing · Form 8-K · Results Reported its results Oct 29, 2025 Insider · 1 person Insiders: 3 sales (~$1.7M) Oct 30, 2025 Insider · 2 people Insiders: 11 sales (~$6.7M) Oct 31, 2025 Insider · 1 person Insiders: 3 sales (~$1.8M) Nov 3, 2025 Insider · 2 people Insiders: 16 sales (~$11.4M) Nov 4, 2025 Insider · 2 people Insiders: 12 sales (~$10.9M) Nov 5, 2025 Insider · 1 person Insiders: 5 sales (~$1.8M) Nov 6, 2025 Insider · 1 person Insiders: 2 sales (~$1.8M) Nov 7, 2025 Insider · 1 person Insiders: 3 sales (~$1.8M) Nov 10, 2025 Insider · 2 people Insiders: 4 sales (~$11.3M) What came next Jan 21, 2026 Company filing · Form 8-K · Executive change, Bylaws or charter Changed a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item) “On January 21, 2026, the Board of Directors (the “ Board ”) of United Therapeutics Corporation (the “ Company ”), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board.” Feb 25, 2026 Company filing · Form 8-K · Results Reported its results Mar 9, 2026 Company filing · Form 8-K · Material agreement, Reg FD Signed an important agreement, and shared information with investors